李芳，女，博士，中药药理与中医药学系副教授，硕士研究生导师。2015年6月博士毕业于中国药科大学生药学专业，获博士学位；同年7月进入中国药科大学博士后流动站从事博士后研究。2018年7月博士后出站并留校在中药学院工作。
研究方向：中药（复方）防治心血管相关疾病的作用机理与药效物质基础研究。作为课题负责人，先后主持了国家自然科学基金青年基金（**），江苏省自然科学基金青年基金（BK**），中国博士后科学基金特别资助（2017T100425），中国博士后科学基金面上一等资助（2016M600456）及中央高校培育项目（2016ZPY018）等多项课题，并作为重要成员参与了多项国家自然科学基金项目。迄今，以第一作者在International Journal of Cardiology等杂志发表多篇SCI论文。
联系方式：
邮箱：lifang**@126.com；lifang@cpu.edu.cn
近两年来代表性成果：
1. Fang Li, Xiaoxue Fan, Yu Zhang, Yuanyuan Zhang, Xiaonan Ma, Junping Kou, Boyang Yu. Inhibition of myosin IIA-actin interaction prevents ischemia/reperfusion induced cardiomyocytes apoptosis through modulating PINK1/Parkin pathway and mitochondrial fission. International Journal of Cardiology, 2018, https://doi.org/10.1016/j.ijcard.2018.04.079.
2. Fang Li, Xiaoxue Fan, Chun Chu, Yu Zhang, Junping Kou, Boyang Yu. A strategy for optimizing the combination of active components based on Chinese medicinal formula Sheng-Mai-San for myocardial ischemia. Cellular Physiology and Biochemistry, 2018, 45: 1455-1471.
3. Fang Li, Yu Zhang, Donglin Zeng, Yu Xia, Xiaoxue Fan, Yisha Tan, Junping Kou, Boyang Yu. The combination of three components derived from Sheng MaiSan protects myocardial ischemic diseases and inhibits oxidative stress via modulating MAPKs and JAK2-STAT3 signaling pathways based on bioinformatics approach. Frontiers in Pharmacology, 2017, 8: 21.
4. Fang Li, Xiaoxue Fan, Yu Zhang, Lizhi Pang, Xiaonan Ma, Meijia Song, Junping Kou, Boyang Yu. Cardioprotection by combination of three compounds from ShengMai preparations in mice with myocardial ischemia/reperfusion injury through AMPK activation-mediated mitochondrial fission. Scientific Reports, 2016, 6: 37114.
5. Fang Li, Xianjie Zheng, Xiaoxue Fan, Kefeng Zhai, Yisha Tan, Junping Kou, Boyang Yu. YiQiFuMai Powder Injection Attenuates Ischemia/Reperfusion-Induced Myocardial Apoptosis Through AMPK Activation.Rejuvenation research, 2016, 19(6): 1-14.